Olshan Frome Wolosky represented ImmunityBio in the transaction.ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has entered into a definitive agreement to acquire a leasehold interest in 409,000 square…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
